Inactive Instrument

Liminal BioSciences Inc. Stock price

Equities

PJ2

CA53272L2021

Biotechnology & Medical Research

Dynamic Chart

Latest transcript on Liminal BioSciences Inc.

Managers TitleAgeSince
Chief Executive Officer 51 08-07-13
Director of Finance/CFO 51 22-03-01
President 49 05-12-31
Members of the board TitleAgeSince
Chief Tech/Sci/R&D Officer 61 19-04-30
Director/Board Member 67 14-05-13
Chairman 60 20-08-31
More insiders
Liminal BioSciences Inc. is a Canada-based is a development-stage biopharmaceutical company. The Company is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The Company is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.
More about the company
  1. Stock
  2. Equities
  3. Stock Liminal BioSciences Inc. - Deutsche Boerse AG